NEW YORK--Molecular Applications Group, which was rumored earlier this year to be struggling to stay afloat, is in negotiations to sell off its proprietary bioinformatics technologies to bidders including Celera and Affymetrix, according to a source close to one of the deals. Officials at Affymetrix and Celera said they would not comment on rumors, and MAG's acting CEO, Debra Yu, declined to comment.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.